227 related articles for article (PubMed ID: 36573513)
1. [ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure].
Di Fusco SA; Spinelli A; Aquilani S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
G Ital Cardiol (Rome); 2023 Jan; 24(1):66-74. PubMed ID: 36573513
[TBL] [Abstract][Full Text] [Related]
2. Italian Association of Hospital Cardiologists practical guidance for sodium-glucose cotransporter 2 inhibitors use in patients with heart failure.
Di Fusco SA; Spinelli A; Aquilani S; Borrelli N; Iannopollo G; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
Eur Heart J Suppl; 2023 May; 25(Suppl D):D287-D293. PubMed ID: 37213801
[TBL] [Abstract][Full Text] [Related]
3. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
4. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
5. The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors.
Chan CG; Stewart R
N Z Med J; 2022 Aug; 135(1560):99-104. PubMed ID: 35999803
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
7. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
Kubica J; Kubica A; Grzelakowska K; Stolarek W; Grąbczewska Z; Michalski P; Niezgoda P; Bartuś S; Budaj A; Dąbrowski M; Drożdż J; Gellert R; Jaguszewski MJ; Jankowski P; Legutko J; Lesiak M; Leszek P; Małyszko J; Mitkowski P; Nessler J; Pawlaczyk K; Siller-Matula J; Stompór T; Wolnik B; Navarese EP
Cardiol J; 2023; 30(1):143-149. PubMed ID: 34708866
[TBL] [Abstract][Full Text] [Related]
9. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
Mordi IR; Lang CC
Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
[TBL] [Abstract][Full Text] [Related]
10. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
[TBL] [Abstract][Full Text] [Related]
11. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
[TBL] [Abstract][Full Text] [Related]
12. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
13. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
14. Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
McKenzie T; Hale GM; Miner A; Colón Colón J; Evins G; Wade J
Heart Fail Rev; 2024 Mar; 29(2):549-558. PubMed ID: 38300379
[TBL] [Abstract][Full Text] [Related]
15. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits.
Dixit NM; Ziaeian B; Fonarow GC
Heart Fail Clin; 2022 Oct; 18(4):587-596. PubMed ID: 36216488
[TBL] [Abstract][Full Text] [Related]
17. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
18. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Vaduganathan M; Januzzi JL
Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
[TBL] [Abstract][Full Text] [Related]
19. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Ojha U; Reyes L; Eyenga F; Oumbe D; Watkowska J; Saint-Jacques H
Am J Cardiovasc Drugs; 2022 Jan; 22(1):35-46. PubMed ID: 34189716
[TBL] [Abstract][Full Text] [Related]
20. The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!
Clark KAA
Postgrad Med J; 2023 Sep; 99(1176):1052-1057. PubMed ID: 37001168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
